Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Nature Medicine

• Publication date

  2018-07-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41591-018-0101-zPMID 30013197
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

  2018cited by this paper
• Association of early reduction in circulating tumor DNA (ctDNA) with improved progression-free survival (PFS) and overall survival (OS) of patients (pts) with urothelial bladder cancer (UBC) treated with durvalumab (D).

  2017cited by this paper
• Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).

  2017cited by this paper
• Development of mesenchymal subtype gene signature for clinical application in gastric cancer

  2017cited by this paper
• Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab.

  2017cited by this paper
• First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer

  2017cited by this paper
• Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2017cited by this paper
• Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability

  2017cited by this paper
• Abstract 582: Circulating tumor DNA (ctDNA) variant allele frequencies are reduced in responders to durvalumab and low baseline variant allele frequencies are associated with improved overall survival in NSCLC patients

  2017cited by this paper
• KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.

  2017cited by this paper
• New insights into the role of EMT in tumor immune escape

  2017cited by this paper
• Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers

  2016cited by this paper
• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

  2016cited by this paper
• Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

  2016cited by this paper
• Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.

  2016cited by this paper
• deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution

  2016cited by this paper
• The Ensembl Variant Effect Predictor

  2016cited by this paper
• Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

  2016cited by this paper
• Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

  2015cited by this paper
• Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

  2015cited by this paper
• Comprehensive molecular characterization of gastric adenocarcinoma

  2014cited by this paper
• Microsatellite instability detection by next generation sequencing.

  2014cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling.

  2011cited by this paper
• Molecular Classification of Gastric Cancer: A New Paradigm

  2011cited by this paper
• The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

  2010cited by this paper
• Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma.

  2010cited by this paper
• The Catalogue of Somatic Mutations in Cancer

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers.

  2006cited by this paper
• Theoretical and practical advances in genome halving

  2004cited by this paper
• Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction.

  2003cited by this paper
• dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation.

  1999cited by this paper

• Decoding the tumor microenvironment remodeling orchestrated by CLEC3B+ inflammatory cancer-associated fibroblasts in lung adenocarcinoma immunotherapy: elucidation from pan-cancer spatially single-cell transcriptomics landscape

  2026cites this paper
• Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Primetime?

  2026cites this paper
• A case report of a patient with advanced gastric adenocarcinoma who demonstrated excellent long-term sustained efficacy even after discontinuation of treatment following chemotherapy combined with claudin18.2 and PD-1 therapy

  2026cites this paper
• Targeting Esophageal Cancer: Promising Drugs for the Clinical Landscape and Key Knowledge Gaps

  2026cites this paper
• Collagen-mediated pro-tumorigenic MAPK activation drives stromal-immune reprogramming in solid cancers

  2026cites this paper
• Identifying Subsets of Patients with Non-immunogenic Gastrointestinal Cancers for Checkpoint Immunotherapy

  2026cites this paper
• Salvage Re-Gastrectomy for Isolated Locoregional Recurrence After Curative Gastrectomy: A Propensity-Matched Comparative Analysis

  2026cites this paper
• TRP channel expression patterns define molecular subtypes, prognosis, and therapeutic targets in gastric cancer

  2026cites this paper
• Harnessing Anoikis-Related Gene Signatures for Immunotherapy Precision: A Machine Learning-Driven Predictive and Prognostic Model.

  2026cites this paper
• Clinical response of immunotherapy targeting programmed cell death receptor 1/programmed cell death ligand 1 in advanced signet-ring-cell gastric cancer.

  2026cites this paper
• Prognostic value of ctDNA-derived maximum somatic allele frequency in patients with metastatic gastric cancer

  2026cites this paper
• The emerging landscape of lncRNAs in gastric cancer immunity: From immune escape to ferroptosis and metabolic reprogramming.

  2026cites this paper
• Real-World Genomic Landscape of Korean Gastric Cancer: Integrating Biomarker Associations and Clinical Outcomes in Metastatic Gastric Cancer.

  2026cites this paper
• Association between the presence of malignant ascites and survival outcomes in gastric cancer patients treated with nivolumab plus chemotherapy.

  2026cites this paper
• Association of copy number alterations with the immune transcriptomic landscape in cancer

  2026cites this paper
• Longitudinal plasma proteome profiling identifies IFN-gamma dynamics as a time-dependent predictor of immunotherapy response in advanced gastric cancer

  2026cites this paper
• Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer.

  2026cites this paper
• The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer.

  2026cites this paper
• Identification of a Tertiary Lymphoid Structure Signature for Predicting Tumor Outcomes Through Transcriptomics Analysis.

  2026cites this paper
• Predictive Value of Insertion/Deletion Rate in Patients With Gastric Cancer Treated With Nivolumab Plus Chemotherapy

  2026cites this paper
• [Heterogeneity of mismatch repair protein expression in tumors].

  2026cites this paper
• Identification of Immune&Driver Molecular Subtypes Optimizes Immunotherapy Strategies for Gastric Cancer

  2026cites this paper
• Epstein-Barr Virus Associated Gastric Carcinoma: A Clinicopathologic Study with Recognition of a Distinctive Reticular Histologic Pattern.

  2026cites this paper
• Immune microenvironment and treatment response of dMMR gastric cancer: Heterogeneity and implications for immunotherapy

  2026cites this paper
• TiRank prioritizes phenotypic niches in tumor microenvironment for clinical biomarker discovery

  2026cites this paper
• Research progress on the correlation between OPN and immune escape of gastric cancer

  2026cites this paper
• Targeting JAK/STAT axis in solid tumors: resolving the therapeutic paradox through upstream suppression and downstream disruption

  2026cites this paper
• Artificial intelligence–enabled multi-omics biomarkers for immune checkpoint blockade: mechanisms, predictive modeling, and clinical translation

  2026cites this paper
• Association between splenic volume changes and prognosis in advanced gastric cancer patients receiving chemotherapy combined with immunotherapy.

  2026cites this paper
• Association of clinicopathological characteristics and baseline peripheral blood lymphocyte subsets with efficacy of first-line immunotherapy in advanced gastric cancer

  2026cites this paper
• The efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone in advanced or metastatic gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials

  2025cites this paper
• Evaluating the Potential of COL8A1 as a Therapeutic Target for Chemoresistance, Disease Progression, and a Prognostic Marker in Gastric Cancer

  2025cites this paper
• Comprehensive analysis of single-cell and bulk RNA sequencing data reveals an EGFR signature for predicting immunotherapy response and prognosis in pan-cancer

  2025cites this paper
• Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer

  2025cites this paper
• Chaperonin containing TCP1 subunit 5 as a novel pan-cancer prognostic biomarker for tumor stemness and immunotherapy response: insights from multi-omics data, integrated machine learning, and experimental validation

  2025cites this paper
• Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer

  2025cites this paper
• A comprehensive proteomic analysis uncovers novel molecular subtypes of gastric signet ring cell carcinoma: Identification of potential prognostic biomarkers and therapeutic targets

  2025cites this paper
• Blockade of CLEVER-1 restrains immune evasion and enhances anti-PD-1 immunotherapy in gastric cancer

  2025cites this paper
• Deciphering the Immunomodulatory Function of GSN + Inflammatory Cancer‐Associated Fibroblasts in Renal Cell Carcinoma Immunotherapy: Insights From Pan‐Cancer Single‐Cell Landscape and Spatial Transcriptomics Analysis

  2025cites this paper
• Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer

  2025cites this paper
• Tumor immune microenvironment remodeling after neoadjuvant therapy in gastric cancer: Update and new challenges.

  2025cites this paper
• Assessment of Circulating Tumor DNA Burden in Patients With Metastatic Gastric Cancer Using Real-World Data

  2025cites this paper
• Viral oncogenesis in cancer: from mechanisms to therapeutics

  2025cites this paper
• Novel Composite Scoring System for Predicting Prognosis in Stage IV Gastric Cancer Patients Treated with Immune Checkpoint Inhibitors

  2025cites this paper
• Predicting Immunotherapy Efficacy with Machine Learning in Gastrointestinal Cancers: A Systematic Review and Meta-Analysis

  2025influential citation
• COL1A1-positive endothelial cells promote gastric cancer progression via the ANGPTL4-SDC4 axis driven by Endothelial-to-Mesenchymal Transition.

  2025cites this paper
• Predictive value of EBV-positivity in patients with gastric cancer treated with first-line nivolumab plus chemotherapy

  2025cites this paper
• PathNetDRP: a novel biomarker discovery framework using pathway and protein–protein interaction networks for immune checkpoint inhibitor response prediction

  2025cites this paper
• Mechanism of Rabdosia rubescens extract against gastric cancer microenvironment by SIRT1/NF-κB/p53 pathway and promoting tumor-associated macrophage polarization.

  2025cites this paper
• Identify Modules Associated with Immunotherapy Response from Mouse Tumor Profiles for Stratifying Cancer Patients

  2025cites this paper
• Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer

  2025cites this paper
• Predictive biomarkers in the era of immunotherapy for gastric cancer: current achievements and future perspectives

  2025influential citation
• Efficacy and safety of PD-1 inhibitors for advanced intrahepatic cholangiocarcinoma with or without MAFLD

  2025cites this paper
• SELP can affect the immune microenvironment of gastric cancer and is associated with poor prognosis

  2025cites this paper
• Single-cell dissection of prognostic architecture and immunotherap response in Helicobacter pylori infection-associated gastric cancer

  2025cites this paper
• Gastric Carcinoma.

  2025cites this paper
• Harnessing technologies to unravel gastric cancer heterogeneity.

  2025cites this paper
• Immunotyping the Tumor Microenvironment Reveals Molecular Heterogeneity for Personalized Immunotherapy in Cancer

  2025cites this paper
• Roles and functions of tumor-infiltrating lymphocytes and tertiary lymphoid structures in gastric cancer progression

  2025cites this paper
• One-Two Punch: Combining Chemotherapy and Immunotherapy to Decrease Radiation Dose and Related Toxicity in Children and Adolescents with Nasopharyngeal Carcinoma.

  2025cites this paper
• CXCL13 Expression Promotes CAR T Cell Antitumor Activity and Potentiates Response to PD‐1 Blockade

  2025cites this paper
• Proteomics analysis and immune profiling reveal regulators of PD-L1 in oesophageal squamous cell carcinoma

  2025cites this paper
• Case Report: A case of synchronous multiple early gastric cancer with a microsatellite instability-high phenotype

  2025cites this paper
• Helicobacter pylori reversing the landscape of neoadjuvant immunotherapy for microsatellite stable gastric cancer: a multicenter cohort study

  2025cites this paper
• CT Scans Understage Lymph Nodes in Gastric and Gastroesophageal Adenocarcinoma

  2025cites this paper
• Advances and challenges in gastric cancer testing: the role of biomarkers

  2025influential citation
• Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice

  2025cites this paper
• Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma

  2025influential citation
• Le diagnostic virologique des maladies associées au virus d’Epstein-Barr

  2025cites this paper
• Recent advances in the mechanisms of PD-L1 expression in gastric cancer: a review

  2025cites this paper
• A Comprehensive Review on Novel Therapies for Gastrointestinal Cancers using Translational Platforms.

  2025cites this paper
• Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy

  2025cites this paper
• TCGEx: a powerful visual interface for exploring and analyzing cancer gene expression data

  2025cites this paper
• Neoadjuvant Strategies for Triple Negative Breast Cancer: Current Evidence and Future Perspectives

  2025cites this paper
• CXCR2P1 enhances the response of gastric cancer to PD-1 inhibitors through increasing the immune infiltration of tumors

  2025cites this paper
• Immune evasion strategies in AFP-producing gastric carcinoma: characterized by HLA-G expression and HLA class I deficiency.

  2025cites this paper
• Helicobacter pylori-related serum indicators: Cutting-edge advances to enhance the efficacy of gastric cancer screening

  2025cites this paper
• Mathematically mapping the network of cells in the tumor microenvironment

  2025cites this paper
• Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis

  2025influential citation
• A CLDN18.2‐Targeted Nanoplatform Manipulates Magnetic Hyperthermia Spatiotemporally for Synergistic Immunotherapy in Gastric Cancer

  2025cites this paper
• Integrated clinico-molecular analysis of gastric cancer in European and Latin American populations: LEGACY project

  2025cites this paper
• Role of Keratin-10 in Tumor Progression and Radioresistance of Laryngeal Cancer Cells

  2025cites this paper
• Targeting both death and paracaspase domains of MALT1 with antisense oligonucleotides overcomes resistance to immune-checkpoint inhibitors

  2025cites this paper
• iMLGAM: Integrated Machine Learning and Genetic Algorithm‐driven Multiomics analysis for pan‐cancer immunotherapy response prediction

  2025cites this paper
• Targeting tumor-intrinsic S100 calcium-binding protein A1 augments antitumor immunity and potentiates immunotherapy efficacy

  2025cites this paper
• Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies

  2025cites this paper
• Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies

  2025cites this paper
• Predictive biomarkers for immunotherapy in gastric cancer

  2025cites this paper
• Residual gastric cancer with a mixed small cell neuroendocrine and keratinizing squamous cell carcinoma: A case report

  2025cites this paper
• The efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials

  2025cites this paper
• Unravelling Cancer Immunity: Coagulation.Sig and BIRC2 as Predictive Immunotherapeutic Architects

  2025cites this paper
• PD-L1 importance in malignancies comprehensive insights into the role of PD-L1 in malignancies: from molecular mechanisms to therapeutic opportunities

  2025cites this paper
• Efficacy and safety of programmed cell death protein-1 inhibitor for first-line therapy of advanced gastric or gastroesophageal junction cancer: a network meta-analysis

  2025cites this paper
• SERPINE1 Facilitates Metastasis in Gastric Cancer Through Anoikis Resistance and Tumor Microenvironment Remodeling.

  2025cites this paper
• The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates

  2025cites this paper
• Unraveling the Role of Programmed Cell Death Gene Signature and THBS1 in Gastric Cancer Progression and Therapy Response

  2025cites this paper
• Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer.

  2025cites this paper
• Association Between Epstein–Barr Virus Infection and PD-L1 Expression in Gastric Cancer: Prevalence, Clinicopathological Features, and Prognostic Implications

  2025cites this paper
• Identification of PD-L1-related biomarkers for selecting gastric adenocarcinoma patients for PD-1/PD-L1 inhibitor therapy

  2025cites this paper
• Mapping the landscape of gastric cancer immunotherapy: Bibliometric insights into advances and hotspots

  2025cites this paper